APLMW

Apollomics Inc. operates as a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies. Headquartered in Foster City, California, the company employs a precision medicine approach to target specific cancer pathways through its pipeline of small molecule and immunotherapy candidates. The company's lead programs include vebreltinib (APL-101), an oral c-Met inhibitor in clinical trials for non-small cell lung cancer and other solid tumors, and uproleselan (APL-106), a selectin inhibitor being evaluated in acute myeloid leukemia. Apollomics also develops APL-501, a differentiated multi-kinase inhibitor, and APL-601, an antibody-drug conjugate targeting c-Met-expressing tumors. The company operates through a combination of proprietary drug development and strategic partnerships with academic institutions and pharmaceutical companies in China and globally. Apollomics maintains research collaborations and licensing agreements to expand its oncology portfolio while managing clinical trial operations across multiple geographies. In recent developments, the company continues advancing its pipeline through Phase I and Phase II clinical trials, with particular focus on biomarker-driven patient selection to improve therapeutic outcomes. Apollomics trades on the Nasdaq Capital Market and pursues a capital-efficient development strategy by leveraging partnerships and focusing resources on programs with differentiated mechanisms of action in underserved cancer populations.